FDA Review Of Novartis' Entresto Shows Agency's Practical Side
Executive Summary
Pivotal trial of Novartis' sacubitril/valsartan duo in heart failure did not conform to FDA's combination policy, but agency ultimately valued its mortality effect over statistical correctness.